Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
Replidyne, Inc. today announced results from three Phase I trials studying REP8839, a novel topical antibiotic that has shown potent in vitro activity against major skin pathogens including methicillin-resistant S. aureus (MRSA). The results of the Phase I trials show that topically applied REP8839 appears safe, well-tolerated and associated with low systemic exposure, or drug abso...Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
LOUISVILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/ --Replidyne, Inc. today announced results from three Phase I trialsstudying REP8839, a novel topical antibiotic that has shown potentin vitro activity against major skin pathogens includingmethicillin-resistant S. aureus (MRSA). The results of the Phase Itrials show that topically applied REP8839 appears safe,well-tolerated and asso...Replidyne Phase II Pediatric Trial Meets Primary Objective
LOUISVILLE, Colo., March 06, 2007 /PRNewswire-FirstCall/ --Replidyne, Inc. announced today that it has completed its Phase IIclinical trial using faropenem medoxomil (faropenem) in pediatricpatients with acute otitis media (AOM), a common infection of themiddle ear. Initial analyses of the study results show that it metits primary objective to show that faropenem was effective ineradicat...